randomized, randomized studies, randomized study, clinical trial, clinical trials, phase 3, and phase 3 clinical trial.
We identified a total of 277 articles. We excluded noninterventional studies, meta-analyses, review articles, and studies reporting on other than first-line treatments (ie, stem cell transplantation, maintenance strategies, and treatment of relapsed disease or second-line therapies). Articles reporting updated analyses on previously published studies were included. We included all prospective phase 3 studies addressing front-line therapy and select phase 2 studies that enrolled 100 or more patients with CLL. We limited our search to articles published in peer-reviewed journals and excluded reports having only abstracts or presentations at scientific meetings. The bibliography of each article was reviewed to find any studies missed using our search strategy.
Our search and inclusion criteria yielded 24 articles (eFigure in the Supplement). Where appropriate, the level of evidence for therapeutic recommendations is presented as previously described (level I: randomized trials with low false-positive rates; level II: randomized trials with high false-positive or high false-negative rates; level III: nonrandomized concurrent cohort comparisons; level IV: nonrandomized historical cohort comparisons; level V: case series without controls). 4 
Diagnosis and Risk Stratification of CLL
Features related to the initial presentation and diagnosis of CLL are reported in Box 1. The disease is characterized by the progressive accumulation of phenotypically mature malignant B lymphocytes, primarily in the peripheral blood, bone marrow, and lymph nodes. These cells are small, with a narrow border of cytoplasm, a dense nucleus without nucleoli, and aggregated chromatin. The characteristic presence of smudge cells that result from lymphocyte debris as the peripheral smear is being prepared has been a pathognomonic feature of CLL ( Figure) .
The National Cancer Institute (NCI)-sponsored working group guidelines for the diagnosis of CLL require an absolute clonal lymphocyte count of 5000 cells/mm 3 or more and a characteristic phenotype combining the presence of CD19, the T-cell antigen CD5, and CD23. The expression of CD20 is generally weak, and the malignant cells are either κ or λ light chain restricted ( Figure) . 5 This immunophenotype is essential to differentiate CLL from other lymphoproliferative disorders, for which management might be fundamentally different. Small lymphocytic lymphoma occurs when CLL cells spare the peripheral blood and the bone marrow but infiltrate the lymph nodes and other tissues. Small lymphocytic lymphoma occurs in 5% of patients with CLL; management is the same as that for conventional CLL. 6 The majority of patients are asymptomatic at the time of presentation, and the diagnosis is often made when coincidental leukocytosis and lymphocytosis are noted on routine laboratory examination. Histologic confirmation by a lymph node biopsy is not routinely needed when the diagnosis is confirmed using flow cytometry of the peripheral blood and is reserved for cases in which different or transformed lymphoid malignancy are thought to coexist with CLL. Monoclonal B lymphocytosis (MBL) occurs in otherwise healthy adults having peripheral blood clonal B lymphocytes but fewer than the minimum of 5000 cells/mm 3 required to diagnose CLL. These patients lack other features of CLL such as adenopathy or constitutional symptoms, and 1% to 2% cases of MBL progress to CLL per year. 7 Monoclonal B lymphocytosis occurs in 5.1% of all people with normal complete blood cell counts and 13.9% of patients with lymphocytosis. It is not known if MBL and CLL have similar molecular features or cytogenetic abnormalities, but recent reports suggest that most patients with CLL have a preceding MBL phase and that advancing age, along with high initial lymphocyte counts, predispose to faster progression to CLL.
8
The Rai and Binet CLL staging systems are used to classify patients with CLL, although both systems are not very effective for predicting early disease progression (Table 1) .
9,10 Although routine imaging is not recommended for staging of patients with CLL, visceral adenopathy may occur in early-stage disease and might predict disease progression. 11 It is not known if the presence of visceral adenopathy warrants any specific change in therapy. Chronic lymphocytic leukemia does not require treatment until symptoms develop or the disease progresses, causing severe cytopenia.
5 Routine imaging studies are not recommended in initial staging or as interim assessments unless dictated by clinical trials.
5
Numerous clinical and molecular features are predictive of the course of CLL and can be used for risk stratification (Box 2).
12,13

CLL Upfront Therapy
Historically, CLL was treated with alkylating agent and purine analogue chemotherapies. Recently, the addition of anti CD-20
Box 1. Initial Presentation and Diagnosis of Chronic Lymphocytic Leukemia (CLL)
Clinical Presentation
• Majority of patients are asymptomatic at diagnosis. Referral is generated when elevated white blood cell counts, lymphocyte counts, or both are noted on routine blood cell counts • Ten percent of patients present with B symptoms (unexplained fevers, unintentional >10% body weight loss in the preceding 6 months, or drenching night sweats) • Most patients have enlarged and palpable lymph nodes on examination • Hepatosplenomegaly may be noted on physical examination in 20% to 50% of patients at presentation
Laboratory Abnormalities
• Absolute lymphocytosis defined as more than 5000 cells/μL • Autoimmune hemolytic anemia may be present at diagnosis in 1% to 11% of cases • Autoimmune thrombocytopenia present at diagnosis in less than 2% of cases • Levels of low-density lipoprotein cholesterol and β2 microglobulin are variably elevated • Hypogammaglobulinemia is present in 8% to 10% of patients at diagnosis
Establishing the Diagnosis
• Flow cytometry and immunophenotyping of the peripheral blood to establish clonality of circulating lymphocytes • Lymphocytes usually express CD19, CD20, CD23, and CD5 • Imaging studies are not required to establish a diagnosis of CLL • Bone marrow biopsy and aspirate is not routinely required to establish a diagnosis but might be indicated to investigate causes of cytopenias should they exist • Lymph node biopsy is not routinely needed to diagnose CLL; biopsy might be clinically indicated if transformation or a concurrent alternate lymphoid malignancy exists immunotherapy to chemotherapeutic treatment of CLL has improved survival, resulting in front-line treatment now recommended as combined immunochemotherapy (Box 3). Treatment is not initiated until CLL is symptomatic or the disease progresses (Box 4). High-risk patients should be enrolled into clinical trials that explore novel therapy, early therapy, or both before symptoms develop. Although randomized studies have not shown an overall survival benefit for purine analogues relative to alkylating agents for front-line CLL treatment, purine analogues have better overall and complete response rates and better progression-free survival. Consequently, purine analogues are now the preferred chemotherapeutic agents for front-line CLL treatment.
14 Long-term follow-up of the original study comparing the purine analogue fludarabine with the alkylating agent chlorambucil suggests a survival advantage in favor of fludarabine. ity evidence that the combination of fludarabine and cyclophosphamide results in better outcomes than fludarabine alone, resulting in fludarabine and cyclophosphamide becoming the new standard to which other chemotherapy combinations are compared.
Chemoimmunotherapy
Monotherapy using rituximab, a chimeric anti-CD20 monoclonal antibody, is very effective as a treatment for indolent lymphomas 22, 23 but not for CLL. The safety of this antibody, coupled with its predictable pharmacokinetics and half-life, makes it an attractive anticancer drug. Consequently, studies were performed to explore its utility for treating CLL as part of a combination chemoimmunotherapy program. Byrd et al 24 reported on a randomized phase 2 trial that compared concurrent fludarabine and rituximab vs sequential therapy of both agents. Patients in the concurrent treatment group achieved higher complete response and overall response rate, although survival remained similar between both groups. Subsequently, a comparative retrospective analysis conducted using data from patients with similar disease characteristics who received fludarabine alone vs those who were treated with concurrent fludarabine + rituximab in the above-mentioned study 25 showed that the chemoimmunotherapy group provided patients with improved overall and progression-free survival. When fludarabine + cyclophosphamide was combined with rituximab in the front-line setting, overall response rate was 95% and complete response was 70%, as described by Keating et al, 26 who also reported that fludarabine + cyclophosphamide + rituximab induced molecular remission in some patients. However, this regimen was deemed more toxic in patients older than 65 years, who were more likely to prematurely discontinue treatment. 26 This issue, along with the suggested, yet controversial, increase in the incidence of secondary leukemias and myelodysplasias 27 associated with this regimen, led to limiting the use of fludarabine + cyclophosphamide + rituximab to fit and young patients with CLL and adequate renal function. 28 The significant activity noted with fludarabine + cyclophosphamide + rituximab led to the conduct of a prospective phase 3 randomized trial comparing fludarabine + cyclophosphamide + rituximab with fludarabine + cyclophosphamide. In that study, 817 previously untreated, fit patients with CLL and with a median age of 61 years were randomized to either 6 cycles of fludarabine + cyclophosphamide + rituximab or fludarabine + cyclophosphamide. Although fludarabine + cyclophosphamide + rituximab was associated with more toxicity, it also demonstrated better efficacy (overall response rate, 93% vs 85%; complete response, 44.5% vs 23%; P < .001).
3 Importantly, this study was the first to show level I evidence on survival advantage for any combination program in CLL. With a median follow-up that approached 6 Fludarabine (inhibits function of DNA polymerase, primase)
Pentostatin (inhibits enzyme adenosine deaminase, affecting DNA processing)
Cladribine (inhibits adenosine deaminase)
Immunotherapy and Monoclonal Antibodies
Rituximab (anti-CD20)
Lenalidomide (immunomodulatory agent with multiple targets)
B-Cell Receptor Pathway and Tyrosine Kinase Inhibitors
Ibrutinib (targets bruton tyrosine kinase)
Idelalisib (targets phosphoinositide 3-kinase delta)
years, more patients receiving fludarabine + cyclophosphamide + rituximab were alive compared with those receiving fludarabine + cyclophosphamide (69.4% vs 62.3%, P = .001), which corresponded to a median survival of "not reached" in the group receiving fludarabine + cyclophosphamide + rituximab vs 86 months in the group receiving fludarabine + cyclophosphamide.
Other regimens followed as additional chemotherapeutic agents either alone or in combinations were combined with monoclonal antibodies. Universally, these regimens produced higher overall response rates, complete response, and improvements in progression-free survival as compared with chemotherapy (Table 3) . Another chemoimmunotherapy program combined bendamustine with rituximab and provided patients with an overall response rate that approached 90%. 29 This led to a prospective randomized study comparing bendamustine + rituximab with fludarabine + cyclophosphamide + rituximab. Partial results of this study have been presented in an abstract format, but a final analysis has not been published. 30 Alemtuzumab, a humanized monoclonal antibody targeting CD52 ubiquitously present on the surface of the malignant lymphocytes, has also been incorporated into chemotherapy combinations. The fludarabine + cyclophosphamide + rituximab regimen was compared with the fludarabine + cyclophosphamide + alemtuzumab combination, but this study was closed prematurely because of increased toxicity in the alemtuzumab group, solidifying fludarabine + cyclophosphamide + rituximab as the better and safer chemoimmunotherapy regimen. 31 Collectively, the above data support that chemoimmunotherapy should be considered a standard front-line approach in patients with CLL in need of therapy.
32,33 Fludarabine + cyclophosphamide + rituximab appears to be the most effective, with a proven overall survival advantage when used in fit patients with normal renal function. It is plausible to assume that these more effective therapies, coupled with improvements in supportive measures and better understanding of disease biology, have led to incremental survival improvements in patients treated in the contemporary era. A retrospective analysis of Surveillance, Epidemiology, and End Results data has shown that 5-year overall survival for all patients with CLL treated between 2001 and 2009 was significantly better than that for patients treated between 1992 and 2000 (66% vs 60%, P < .001).
34
Emerging Therapies
The B-cell receptor is crucial for the evolution and progression of CLL. Therapies targeted to this receptor and its downstream proteins have been developed. These include the bruton tyrosine kinase inhibitor ibrutinib 35 and the phosphatidylinositol 3-kinase (PI3K) inhibitor idelalisib. 36 Other newly studied agents include drugs targeting the antiapoptotic protein BCL-2 32 and anti-CD20 antibodies that are modified and engineered differently to provide better cell killing.
37,38
Current Guidelines
As treatment strategies have become more complex, various international societies have issued CLL treatment guidelines ( Table 4) . All of these guidelines emphasize the importance of accurate diagnosis and underscore that initial observation without active treatment for patients with CLL is the standard approach for all asymptomatic patients, regardless of their risk category. The National Comprehensive Cancer Network recommends stratifying patients with CLL by cytogenetic analysis and fluorescence in-situ hybridization because some high-risk patients, such as those carrying the 17p deletion, could benefit from early allogeneic bone marrow transplantation (discussed below). All of the guidelines also recommend the use of chemoimmunotherapy in the upfront setting (patients receiving treatment for the first time once they require therapy generally dependent on patients' performance status and comorbidities. The German CLL Study Group classifies patients as fit or unfit based on their renal function (unfit when the glomerular filtration rate is <70 mL/min) and their scores on the cumulative illness rating scale (unfit when the combined score is Ն6). Treatment regimens are then adjusted based on fitness level (Table 4) . 32 As new molecular targets become more integrated into current therapies, these guidelines are likely to be further revised and refined.
Critical Questions in CLL 1. Treating Richter Syndrome
Richter syndrome occurs at a rate of 0.5% to 1% per year in patients with CLL and represents the transformation of CLL into an aggressive lymphoma. 39 Patients with Richter syndrome experience a change in their clinical course and disease behavior, with rapid progression of adenopathy, elevated serum tumor marker levels, and development of B symptoms. 40 The majority of these transformations are compatible with diffuse large B-cell lymphoma histologically, although lower-grade lymphomas and Hodgkin transformation have been described. Although molecular predisposition to Richter syndrome continues to be refined, 41 advanced-stage disease and enlarged lymph nodes (>3 cm on clinical examination) have been proposed as predictors for higher risk of transformation. 41 The contribution of prior CLL therapy to the development of Richter syndrome remains unknown. 42, 43 The prognosis of the syndrome is poor.
Richter syndrome prognostic scores rely on performance status, prior a Upfront indicates that patients receive treatment for the first time once they require therapy. b Recruitment was halted prematurely because of excess toxicity in the fludarabine + cyclophosphamide + alemtuzumab group (8 deaths, 5 from infection) c Twenty percent died in the chlorambucil group, 15% in the chlorambucil + rituximab group, and 9% in the chlorambucil + obintuzumab group. P = .002 for chlorambucil/obintuzumab vs chlorambucil but not significant between chlorambucil/obintuzumab and chlorambucil/rituximab. d Overall survival was better in patients younger than 65 years receiving Fludarabine + cyclophosphamide + subcutaneous alemtuzumab (85% vs 76%, P = .03). e Fitness level is assessed based on serum creatinine level and glomerular filtration rate (<70 mL/min) or geriatric assessment using the Cumulative Illness Rating Scale, with patients scoring higher than 6 on that scale considered unfit. Slow go indicates that patients did not fulfill either criterion (glomerular filtration rate or Cumulative Illness Rating Scale).
Richter syndrome who have a clone unrelated to the underlying CLL, standard therapy for large-cell lymphoma should be pursued. For the bulk of remaining patients, clinical trials are favored, because standard therapies have provided suboptimal results. Outside of clinical trials, it is appropriate to induce patients with Richter syndrome into the best remission possible using intensive chemoimmunotherapy regimens followed by allogeneic transplantation in suitable individuals.
Treating Hemolytic Anemia and Immune-Mediated Thrombocytopenia
Autoimmune hemolytic anemia (AIHA) is a well-known complication of CLL. Mauro et al 45 reported that the incidence of AIHA was 46 The combination of rituximab + cyclophosphamide + dexamethasone to treat refractory AIHA in patients with CLL has proven effective. 46 In the absence of other clear indications to treat the underlying CLL, single-agent rituximab appears to be a reasonable choice, but rituximab + cyclophosphamide + dexamethasone can be considered. In patients with refractory disease, treating the underlying CLL is appropriate. Also, while some observers have suggested that purine analogues could induce AIHA, Dearden et al 47 reported a beneficial effect for the fludarabine + cyclophosphamide combination, because patients receiving that combination had lower incidence of AIHA compared with others receiving chlorambucil.
Immune-mediated thrombocytopenia occurs in 2% to 3% of patients with CLL. The diagnosis is made on clinical grounds by ruling out other causes of thrombocytopenia, which might require performing a bone marrow biopsy to exclude progressive disease infiltration.
6 Evans syndrome is defined when patients have immunemediated thrombocytopenia and AIHA at the same time. Treatment is similar to that for AIHA, although some observers have recommended splenectomy for patients with refractory nonresponding disease. These results and other phase 2 studies argued that chlorambucil is a viable option for older patients with CLL. Accordingly, the German CLL Study Group conducted a prospective phase 3 randomized trial comparing chlorambucil alone with chlorambucil plus either rituximab or obinutuzumab in patients with CLL who had coexisting morbidities defined as either reduced glomerular filtration rate (<70 mL/min) or cumulative score of 6 or more on the Cumulative Illness Rating Scale. 37 Most enrolled patients were older than 70 years and had coexisting medical conditions. The combination of chlorambucil + obinutuzumab proved safe and more effective than the comparator groups. Specifically, overall and progression-free survival favored obinutuzumab + chlorambucil compared with chlorambucil alone (P < .001). Progression-free survival, but not overall survival, favored the obinutuzumab group when compared with rituximab (P < .001). This study was the first specifically designed for patients with CLL and comorbidities and has provided level I evidence on the survival superiority of chemoimmunotherapy over standard chemotherapy.
Other studies have explored immunomodulatory agents such as lenalidomide in this patient population. Strati et al 61 reported the long-term outcomes of 60 patients with CLL older than 65 years who received lenalidomide monotherapy on an escalated dosing schedule. At a median follow-up of 4 years, overall survival was 82%, and time to treatment failure was not reached. Although the definition of elderly varied among studies, future studies in this patient population are starting to incorporate geriatric and comorbidity assessments as opposed to chronological age.
the incidence and severity of infectious complications were less in patients with CLL who received intravenous gamma globulin prophylactic therapy. To that end, this approach is recommended for patients with CLL who have had repeated infectious episodes that can be attributed to hypogammaglobulinemia. Molica et al 63 conducted a crossover study of 42 patients with CLL who received either low-dose gamma globulin prophylaxis every 4 weeks for 6 months or no treatment. A protective effect for gamma globulin was clearly demonstrated. Of importance is the recognition of some unique infectious complications and pathogens that occur when specific therapy is instituted. Cytomegalovirus reactivation occurs in up to 25% of patients receiving alemtuzumab. 64 Prolonged, depressed immune surveillance associated with purine analogues might lead to Listeria or Pneumocystis infections. 65 Although high-quality evidence is lacking, it is reasonable to consider giving prophylactic antiPneumocystis and antiviral prophylaxis to patients with CLL while they are receiving antineoplastic therapy. This recommendation is based on the observation that all contemporary CLL clinical trials used this approach.
Role of Transplantation in CLL
Current evidence supports discussing allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor risk disease, specifically those who harbor the 17p mutation, P53 mutation, or both, even in their first remission. 66 Despite the fact that patients with CLL are diagnosed at an older age, advances in supportive measures, the utilization of reduced-intensity conditioning programs, and successful HSCT from unrelated donors or from those who are less than a complete match have all led to some patients attaining long-term disease control and possible cure. 67 In fact, Sorror et al 68 reported a 2-year overall survival of 60% among 64 patients with advanced CLL who have undergone reduced-intensity conditioning-based allogeneic HSCT. Patients who received a transplant from an unrelated donor fared better than their counterparts, suggesting a beneficial graft vs leukemia effect. Based on the National Comprehensive Cancer Network recommendations, 33 early referral of patients with high-risk CLL to a transplantation center to better coordinate care and plan the induction regime is advised.
Conclusions
Chronic lymphocytic leukemia is a heterogenous disease with variable clinical course that has become more predictable with better understanding of disease biology and newer prognostic factors. Chemoimmunotherapy-specifically, fludarabine + cyclophosphamide + rituximab-has become the default standard in young, fit patients with good renal function, because it was the only combination program to improve overall survival in a randomized phase 3 setting in this patient population. Other regimens are more applicable to older and frailer patients who are unlikely to tolerate fludarabine + cyclophosphamide + rituximab. In fact, the combination of chlorambucil and obinutuzumab has improved survival in older patients with CLL who have comorbidities. Novel targeted therapies mainly directed at disrupting the B cell receptor pathway have emerged as valuable tools in the armamentarium for treating CLL. Whether these biologic agents will replace standard chemotherapy remains to be seen and will certainly be the subject of future prospective clinical trials.
Clinical Bottom Line
• Improvements in response rates, durations of response, progression-free survival, and overall survival have been achieved in patients with CLL.
• Chemoimmunotherapy, the addition of anti-CD20 antibodies to combination chemotherapy, is now the standard approach for patients with CLL receiving treatment for the first time once they require therapy. Despite recent advances in CLL risk stratification, there are no indications to initiate therapy in asymptomatic patients unless in the context of clinical trials.
